Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) has announced positive Phase IIb clinical trial results for its novel anti-inflammatory treatment, CimetrA®. The trial demonstrated significant benefits in COVID-19 patients, including:
- No drug-related adverse events
- Faster clinical improvement compared to placebo (WHO Ordinal Scale)
- Reduced inflammation with modulation of key markers (IL-6, IL-1β, TNF-α)
- Improved quality of life trends
The company is also developing CannEpil®, an oral mucosal solution with high-CBD and low-THC formulation, designed for severe epilepsy treatment. The drug is currently making progress in the UK market.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) ha annunciato risultati positivi della fase IIb di uno studio clinico per il suo nuovo trattamento anti-infiammatorio, CimetrA®. Lo studio ha dimostrato benefici significativi nei pazienti affetti da COVID-19, tra cui:
- Nessun evento avverso correlato al farmaco
- Miglioramento clinico più rapido rispetto al placebo (Scala Ordinale OMS)
- Riduzione dell'infiammazione con modulazione di marcatori chiave (IL-6, IL-1β, TNF-α)
- Tendenze di miglioramento della qualità della vita
L'azienda sta anche sviluppando CannEpil®, una soluzione mucosale orale con formulazione ad alto contenuto di CBD e basso contenuto di THC, progettata per il trattamento dell'epilessia severa. Il farmaco sta attualmente progredendo nel mercato del Regno Unito.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) ha anunciado resultados positivos de la fase IIb de un ensayo clínico para su nuevo tratamiento antiinflamatorio, CimetrA®. El ensayo demostró beneficios significativos en pacientes con COVID-19, incluyendo:
- Sin eventos adversos relacionados con el medicamento
- Mejora clínica más rápida en comparación con el placebo (Escala Ordinal de la OMS)
- Reducción de la inflamación con modulación de marcadores clave (IL-6, IL-1β, TNF-α)
- Tendencias de mejora en la calidad de vida
La empresa también está desarrollando CannEpil®, una solución mucosa oral con formulación de alto CBD y bajo THC, diseñada para el tratamiento de la epilepsia severa. El medicamento está avanzando actualmente en el mercado del Reino Unido.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF)는 새로운 항염증 치료제 CimetrA®에 대한 2b상 임상 시험 결과를 발표했습니다. 이 시험은 COVID-19 환자에서 다음과 같은 중요한 이점을 보여주었습니다:
- 약물 관련 부작용 없음
- 플라시보에 비해 더 빠른 임상 개선 (WHO 서열 척도)
- 핵심 마커(IL-6, IL-1β, TNF-α)의 조절을 통한 염증 감소
- 삶의 질 향상 경향
회사는 또한 심각한 간질 치료를 위해 고CBD 및 저THC 제형의 경구 점막 용액인 CannEpil®를 개발하고 있습니다. 이 약물은 현재 영국 시장에서 진전을 보이고 있습니다.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) a annoncé des résultats positifs de l'essai clinique de phase IIb pour son nouveau traitement anti-inflammatoire, CimetrA®. L'essai a démontré des avantages significatifs chez les patients atteints de COVID-19, notamment :
- Aucun événement indésirable lié au médicament
- Amélioration clinique plus rapide par rapport au placebo (Échelle Ordinale de l'OMS)
- Réduction de l'inflammation avec modulation des marqueurs clés (IL-6, IL-1β, TNF-α)
- Tendances d'amélioration de la qualité de vie
L'entreprise développe également CannEpil®, une solution muqueuse orale avec une formulation riche en CBD et faible en THC, conçue pour le traitement de l'épilepsie sévère. Le médicament progresse actuellement sur le marché britannique.
Argent BioPharma (ASX: RGT, OTCQB: RGTLF) hat positive Ergebnisse der Phase IIb einer klinischen Studie für seine neuartige entzündungshemmende Behandlung CimetrA® bekannt gegeben. Die Studie zeigte signifikante Vorteile bei COVID-19-Patienten, einschließlich:
- Keine medikamentenbezogenen Nebenwirkungen
- Schnellere klinische Verbesserung im Vergleich zur Placebo-Gruppe (WHO Ordinalskala)
- Verminderte Entzündung durch Modulation wichtiger Marker (IL-6, IL-1β, TNF-α)
- Tendenzen zur Verbesserung der Lebensqualität
Das Unternehmen entwickelt auch CannEpil®, eine orale Mukosallösung mit einer hoch-CBD und niedrig-THC Formulierung, die für die Behandlung schwerer Epilepsie konzipiert ist. Das Medikament macht derzeit Fortschritte auf dem britischen Markt.
- Successful Phase IIb trial results for CimetrA with no drug-related adverse events
- Demonstrated clinical efficacy in COVID-19 treatment with faster recovery times
- Proven modulation of multiple inflammatory markers
- Pipeline expansion with two promising drugs: CimetrA and CannEpil
- Market entry progress in UK for CannEpil
- Early-stage development status (Phase IIb) indicates long pathway to full approval
- Focused on competitive COVID-19 treatment market
Key Findings:
- No drug-related adverse events, reinforcing CimetrA®'s safety.
- Faster clinical improvement versus placebo, measured by the WHO Ordinal Scale.
- Reduced inflammation, with significant modulation of key inflammatory markers (IL-6, IL-1β, TNF-α, and more).
- Improved quality of life trends observed in CimetrA®-treated patients.
CEO Roby Zomer stated:
"These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."
With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil® is making waves in the
For further information, please contact:
Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com
Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com
View original content:https://www.prnewswire.com/news-releases/argent-biopharma-expands-pipeline-with-promising-drug-cimetra-302402507.html
SOURCE Argent BioPharma Ltd.
FAQ
What were the key findings of RGTLF's CimetrA Phase IIb trial?
How does Argent BioPharma's CimetrA medication work against COVID-19?
What is the composition of RGTLF's CannEpil epilepsy treatment?
What markets is Argent BioPharma (RGTLF) targeting with CannEpil?
